Literature DB >> 22955316

Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents.

Shingai Machingaidze1, Suzanne Verver, Humphrey Mulenga, Deborah-Ann Abrahams, Mark Hatherill, Willem Hanekom, Gregory D Hussey, Hassan Mahomed.   

Abstract

RATIONALE: Conversions and reversions occur with IFN-γ release assay (IGRA) serial testing, as with the tuberculin skin test (TST). Recent TST conversion is associated with an established risk of developing tuberculosis (TB) disease, but the risk associated with recent IGRA conversions is unknown.
OBJECTIVES: To compare the incidence rate of TB disease after recent QuantiFERON TB Gold In-Tube (QFT) conversion compared with nonconverters.
METHODS: Adolescents with converted IGRA status (QFT converters [n = 534]) and randomly chosen adolescents whose IGRA status had remained negative over a period of 2 years (QFT nonconverters [n = 629]) were identified in a cohort study of TB infection and disease. Subsequent TB disease incidence was compared between the two groups.
MEASUREMENTS AND MAIN RESULTS: For QFT converters, the TB incidence rate (all cases) was 1.46 cases per 100 person-years (95% confidence interval [CI], 0.82-2.39), and the cumulative incidence was 2.8% (95% CI, 1.58-4.59). A significantly lower TB incidence rate (0.17 cases per 100 person-yr [95% CI, 0.02-0.62]) and cumulative incidence (0.32% [95% CI, 0.03-1.14]) was observed for QFT nonconverters. The incidence rate ratio was 8.54 (95% CI, 2.51-29.13) for all cases of TB and 9.1 (95% CI, 1.65-50.36) for protocol-defined TB.
CONCLUSIONS: Recent QFT conversion was indicative of an approximately eight fold higher risk of progression to TB disease (compared with nonconverters) within 2 years of conversion in a cohort of adolescents in a high-TB burden population.

Entities:  

Mesh:

Year:  2012        PMID: 22955316     DOI: 10.1164/rccm.201206-1134OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  28 in total

1.  Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers.

Authors:  Madeline L Slater; Gary Welland; Madhukar Pai; Julie Parsonnet; Niaz Banaei
Journal:  Am J Respir Crit Care Med       Date:  2013-10-15       Impact factor: 21.405

2.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

3.  Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

Authors:  Elisa Nemes; Virginie Rozot; Hennie Geldenhuys; Nicole Bilek; Simbarashe Mabwe; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Alana Keyser; Asma Toefy; Yolundi Cloete; Frances Ratangee; Thomas Blauenfeldt; Morten Ruhwald; Gerhard Walzl; Bronwyn Smith; Andre G Loxton; Willem A Hanekom; Jason R Andrews; Maria D Lempicki; Ruth Ellis; Ann M Ginsberg; Mark Hatherill; Thomas J Scriba
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

Review 4.  Tuberculosis susceptibility and protection in children.

Authors:  Robindra Basu Roy; Elizabeth Whittaker; James A Seddon; Beate Kampmann
Journal:  Lancet Infect Dis       Date:  2018-10-12       Impact factor: 25.071

5.  The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.

Authors:  Jason R Andrews; Mark Hatherill; Hassan Mahomed; Willem A Hanekom; Monica Campo; Thomas R Hawn; Robin Wood; Thomas J Scriba
Journal:  Am J Respir Crit Care Med       Date:  2015-03-01       Impact factor: 21.405

6.  Adults with Mycobacterium tuberculosis infection and pre-diabetes have increased levels of QuantiFERON interferon-gamma responses.

Authors:  Matthew J Magee; Susanna L Trost; Argita D Salindri; Genet Amere; Cheryl L Day; Neel R Gandhi
Journal:  Tuberculosis (Edinb)       Date:  2020-04-02       Impact factor: 3.131

Review 7.  Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.

Authors:  Madhukar Pai; Claudia M Denkinger; Sandra V Kik; Molebogeng X Rangaka; Alice Zwerling; Olivia Oxlade; John Z Metcalfe; Adithya Cattamanchi; David W Dowdy; Keertan Dheda; Niaz Banaei
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

Review 8.  Tuberculosis vaccines and prevention of infection.

Authors:  Thomas R Hawn; Tracey A Day; Thomas J Scriba; Mark Hatherill; Willem A Hanekom; Thomas G Evans; Gavin J Churchyard; James G Kublin; Linda-Gail Bekker; Steven G Self
Journal:  Microbiol Mol Biol Rev       Date:  2014-12       Impact factor: 11.056

9.  In vitro immunomodulation for enhancing T cell-based diagnosis of Mycobacterium tuberculosis infection.

Authors:  Madeline Slater; Minh-Chi Tran; Lauren Platt; Lien T Luu; Ha T Phan; Phuong T Pham; Tam B Do; Hanh T Nguyen; Rajiv L Gaur; Julie Parsonnet; Adithya Cattamanchi; Robert Luo; Payam Nahid; Niaz Banaei
Journal:  Diagn Microbiol Infect Dis       Date:  2015-05-19       Impact factor: 2.803

10.  Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence.

Authors:  A Trajman; R E Steffen; D Menzies
Journal:  Pulm Med       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.